AATec Medical Makes Significant Strides in First Year of Operations

AATec Medical GmbH has reported major advancements in its first year of operations. The company, focused on developing therapies based on recombinant alpha-1 antitrypsin (AAT), has made notable progress with its lead candidate, ATL-105, aimed at treating inflammatory lung diseases. Preparations are underway for a clinical trial in non-cystic fibrosis bronchiectasis (NCFB) set to commence in 2025.

The Munich-based biotech firm has engineered a robust manufacturing process for ATL-105 and co-developed an inhaler device with its partner Beurer. Strategic partnerships and a network of high-level scientific advisors have also been established, significantly expanding AATec's IP position.

Co-founders Dr. Rüdiger Jankowsky and Dr. Karsten Ottenberg express pride in these achievements, highlighting the significant interest from clinicians and the pharmaceutical industry. The company is preparing to close its Series A financing round by Q4 2024 to support the upcoming clinical trials.